Longeveron (NASDAQ:LGVN) stock continues to rally on Thursday as investors celebrate positive trial news from the clinical-stage biotechnology company.The big news that boosted shares of LGVN stock higher was investigator data from a Phase 2 trial of Lomocel-B. This is the company’s treatment candidate for patients suffering from hypoplastic left heart syndrome (HLHS).The Phase 2 trial of Lomocel-B is still ongoing and the investigator meeting was positive. That’s a win for the company and investors in LGVN ...